While ColoAlert is the crowning jewel, Mainz Biomed's portfolio is rich with cutting-edge solutions aimed at various diagnostic challenges. If approved, ColoAlert would open up a new realm of possibilities, not just for Mainz Biomed, but for patients across the globe who can benefit from this less invasive, affordable, and accurate method of diagnosis.īaechler is optimistic, "FDA approval of ColoAlert would validate our relentless work and open up avenues for us to make a bigger impact in the healthcare landscape." Investors await as the feasibility studies and branding campaigns ignite. Mainz Biomed stands on the precipice of a breakthrough that could very well be a game-changer in the world of diagnostics and, in turn, could make it's affordable non-invasive testing a household item in the medicine cabinet of many households. MYNZ Intends and Prepares to Pursue FDA Approval.ĬoloAlert is currently conducting 2 feasibility studies, to prepare for its pivotal FDA pre market study. Validating the corporate strategic initiatives, Mainz Biomed announced its footprint expansion into Spain and Portugal on April 26, Poland On May 31st, and Romania in June 0f 2023.Ī Potential Game Changer in Non-Invasive Cancer Detection. In Q1 2023, the MYNZ announce revenue increase of 152% compared to Q1, 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |